What is the recommended way to restart Wegovy (semaglutide) after being off it for four weeks, and at what dose should I begin if I previously tolerated the 1.7 mg dose well?

Restarting Wegovy After 4 Weeks Off

Since you tolerated 1.7 mg well previously and have been off for exactly 4 weeks (which equals 2 consecutive missed doses), you should restart at 1.0 mg and titrate up to 1.7 mg over 4 weeks, rather than resuming directly at 1.7 mg. 1

FDA-Approved Restart Protocol

The official Wegovy prescribing information provides clear guidance for your situation 1:

• If 2 or more consecutive doses are missed: Resume dosing as scheduled OR reinitiate and follow the dose escalation schedule to reduce gastrointestinal symptoms

Four weeks off equals approximately 4 missed weekly doses, placing you firmly in the "2 or more consecutive doses" category.

Recommended Restart Approach

Start at 1.0 mg weekly for 4 weeks, then advance to 1.7 mg 1. This approach:

• Skips the initial 0.25 mg and 0.5 mg doses (since you previously tolerated higher doses)
• Provides one intermediate step before returning to your maintenance dose
• Minimizes risk of severe gastrointestinal adverse events that can occur with abrupt resumption

The 2022 AGA Clinical Practice Guideline supports this strategy, stating that clinical judgment should guide subsequent dosing after missed doses, with consideration for lowering the next dose rather than resuming at the same level 2. While the guideline notes that resuming at the same dose "can be considered" if medication was tolerated well, this applies specifically to situations with fewer than 2 consecutive missed doses—not your 4-week gap.

Why Not Resume Directly at 1.7 mg?

A recent 2026 case report documented severe gastrointestinal intolerance requiring 4-day hospitalization in a patient who restarted semaglutide 2.4 mg after only a 5-week interruption, despite having tolerated it for a full year previously 3. The patient developed:

• Severe nausea, vomiting, and diarrhea within 24 hours
• Significant electrolyte abnormalities
• Required IV hydration and antiemetics

This case emphasizes that previous tolerance does not guarantee tolerance after treatment interruption, even relatively brief ones.

Alternative Conservative Approach

If you experience any gastrointestinal symptoms at 1.0 mg, consider an even more gradual restart:

• Week 1-4: 0.5 mg weekly
• Week 5-8: 1.0 mg weekly
• Week 9+: 1.7 mg weekly

This mirrors the standard titration schedule more closely 4, 5 and may be particularly appropriate if you had any GI side effects during your initial titration.

Critical Safety Considerations

Monitor for gastrointestinal adverse events during restart 2:

• Nausea, vomiting, diarrhea (most common, occurring in 40%, 16%, and similar percentages respectively)
• Severe symptoms warrant dose reduction or temporary discontinuation
• If intolerable symptoms occur, delay dose escalation by an additional 4 weeks

If you have diabetes: Check blood glucose before restarting and monitor closely, especially if taking insulin or sulfonylureas, as dose adjustments may be needed to prevent hypoglycemia 2, 1

Avoid this mistake: Do not restart at 0.25 mg unless you experienced significant GI issues during your original titration. Starting too low unnecessarily prolongs the time to therapeutic effect and may reduce adherence.

Maintenance Dosing

Once you reach 1.7 mg and tolerate it well for at least 4 weeks, you can either:

• Continue at 1.7 mg as your maintenance dose (this is FDA-approved) 1
• Advance to 2.4 mg if you desire additional weight loss and tolerate 1.7 mg without issues

Real-world data from 2026 shows that 40% of patients remain on ≤1.0 mg and 30% on 1.7 mg as their long-term maintenance dose, with substantial weight loss (-13.6% at 12 months) even at these submaximal doses 6. The 2.4 mg target is recommended but not mandatory if you achieve satisfactory results at 1.7 mg 1.